MannKind Corp (MNKD)

• Market cap: $1.42B
• 1 day: 1.52%
• 5 days: 3.77%
• 1 month: -10.52%
• 3 months: -22.39%
• 6 months: -27.33%
• Year to date: -29.09%
• 1 year: 11.69%
• 5 years: 262.79%
• 10 years: -80.50%
• Sector: Healthcare
• Industry: Biotechnology

About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Employees: 407

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

78% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 51

74% more call options, than puts

Call options by funds: $20.3M | Put options by funds: $11.7M

58% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 26

11% more capital invested

Capital invested by funds: $970M [Q3] → $1.08B (+$109M) [Q4]

5% more funds holding

Funds holding: 229 [Q3] → 240 (+11) [Q4]

4.72% more ownership

Funds ownership: 56.12% [Q3] → 60.84% (+4.72%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 156% upside
• Avg. target: $12 156% upside
• High target: $12 156% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Mizuho

156% upside $12

Outperform Initiated

10 Apr 2025